Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
National
Jane Kirby

NHS approves breakthrough drug that can delay type 1 diabetes for years

  • The National Institute for Health and Care Excellence (NICE) has approved teplizumab (Tzield) for use in the NHS, marking a significant advancement in type 1 diabetes treatment.
  • This first-of-its-kind therapy can delay the onset of symptomatic type 1 diabetes by an average of nearly three years, offering patients valuable time before needing aggressive management.
  • Teplizumab is approved for children aged eight and over and adults who have early-stage type 1 diabetes before symptoms appear, training the immune system to prevent it from attacking pancreatic cells.
  • The treatment involves a one-off course of daily infusions over 14 days, with an estimated 1,100 people eligible in the first year.
  • Diabetes UK has hailed the approval as a “landmark moment” and the “start of a new age of type 1 diabetes treatment,” with ongoing studies to screen and identify eligible individuals.

IN FULL

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.